Literature DB >> 15704711

Influence of pre-treatment bacillary load on treatment outcome of pulmonary tuberculosis patients receiving DOTS under revised national tuberculosis control programme.

Rupak Singla1, Neeta Singla, Rohit Sarin, V K Arora.   

Abstract

OBJECTIVE: To study the influence of initial bacillary load on sputum conversion rates and treatment outcome of new smear positive pulmonary tuberculosis patients.
METHODS: A retrospective study was done among 2938 new smear positive pulmonary tuberculosis patients, registered at the peripheral centres, covering a population of 1.6 million in Delhi, India. The patients pre-treatment sputum smears were graded as 1+, 2+ or 3+ based on three samples. Patients were given intermittent short-course chemotherapy under supervision and the treatment outcome was analysed.
RESULTS: Sputum conversion rates among patients graded as sputum 3+ and rest of the patients (combined graded sputum 1+ and 2+) at the end of two months were 62.2% and 76.8% respectively (p<0.001), and at the end of three months were 81.3% and 89.5% respectively (p<0.001). Cure rates among same group of patients were 76.6% and 85.1% respectively (p<0.001), and failure rates were 7.7% and 4.5% respectively (p<0.001).
CONCLUSIONS: Under field conditions even with directly observed treatment (DOT) new smear positive patients with heavy bacillary load showed statistically significant poor sputum conversion rates at two and three months and higher failure rates as compared to patients with lesser bacillary load. To investigate possible reasons for this poor response and possible solutions further studies are needed.

Entities:  

Mesh:

Year:  2005        PMID: 15704711

Source DB:  PubMed          Journal:  Indian J Chest Dis Allied Sci        ISSN: 0377-9343


  9 in total

1.  Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda.

Authors:  E Namukwaya; F N Nakwagala; F Mulekya; H Mayanja-Kizza; R Mugerwa
Journal:  Afr Health Sci       Date:  2011-08       Impact factor: 0.927

Review 2.  CT and 18F-FDG PET abnormalities in contacts with recent tuberculosis infections but negative chest X-ray.

Authors:  Soon Ho Yoon; Jin Mo Goo; Jae-Joon Yim; Takashi Yoshiyama; JoAnne L Flynn
Journal:  Insights Imaging       Date:  2022-07-07

3.  A study of sputum conversion in new smear positive pulmonary tuberculosis cases at the monthly intervals of 1, 2 & 3 month under directly observed treatment, short course (dots) regimen.

Authors:  S Bawri; S Ali; C Phukan; B Tayal; P Baruwa
Journal:  Lung India       Date:  2008-07

4.  Time of default in tuberculosis patients on directly observed treatment.

Authors:  Geeta S Pardeshi
Journal:  J Glob Infect Dis       Date:  2010-09

5.  Treatment outcomes among new smear positive and retreatment cases of tuberculosis in Mangalore, South India - a descriptive study.

Authors:  N Joseph; K Nagaraj; J Bhat; Ryp Babu; Sm Kotian; Yp Ranganatha; Aa Hocksan; Vv Shetty; Nm Zaki; Ks Swasthik; Nf Hamzah
Journal:  Australas Med J       Date:  2011-04-30

6.  A Retrospective Analysis of Two-Month Sputum Smear Non-Conversion in New Sputum Smear Positive Tuberculosis Patients in the Free State Province, South Africa.

Authors:  Nanteza Gladys Kigozi; Perpetual Chikobvu; James Christoffel Heunis; Sonja van der Merwe
Journal:  J Public Health Afr       Date:  2014-07-09

7.  An Analysis of Failure of Category II DOTS Therapy.

Authors:  Subodh K Katiyar; Shailesh Bihari; S Arun; Tara Rawat
Journal:  Indian J Community Med       Date:  2008-04

8.  High mortality during tuberculosis treatment does not indicate long diagnostic delays in Vietnam: a cohort study.

Authors:  Marleen Vree; Nguyen T Huong; Bui D Duong; Nguyen V Co; Dinh N Sy; Frank G Cobelens; Martien W Borgdorff
Journal:  BMC Public Health       Date:  2007-08-16       Impact factor: 3.295

9.  Predictors of recurrent TB in sputum smear and culture positive adults: a prospective cohort study.

Authors:  Grace Muzanyi; Y Mulumba; Paul Mubiri; Harriet Mayanja; John L Johnson; Ezekiel Mupere
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.